PDCD1 and hepatocellular carcinoma: In addition, the combination of Galunisertib and Nivolmab, a new inhibitor of programmed cell death-1 (PD-1) from Merck Sharp and Dohme (MSD), for the treatment of bone marrow hyperplasia and hepatocellular carcinoma, has entered a phase III multicenter clinical trial [7].